Published: Apr 22, 2021
MONTREAL, April 22, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma, Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that RB Capital has injected an additional investment of $500,000 to augment the Company’s Coronavirus drug development program. In addition, RB Capital has provided the Company with assurances that it will continue to provide funding over the next 30 days for the Company’s other R&D activities, including Ada-27a anticancer drug.
Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are very pleased to continue our relationship with RB Capital as long-term investor in the Company. They truly understand our vision and are prepared to help us reach our exciting drug development objectives.”
Published: Apr 19, 2021
MONTREAL, April 19, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma, Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dose (MTD) study in mice. Sunshine Biopharma is pleased to report that the MTD results are favorable and fall within the optimum range for use in humans. Next, Sunshine Biopharma will use the test dose indicated by these results to conduct the efficacy studies in hACE2-transgenic mice.
Sunshine Biopharma’s COVID-19 treatment is an inhibitor of PLpro, a protease present only in the SARS Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host innate immune system thereby causing significantly greater morbidity.
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)
News provided by
Share this article
SHENZHEN, China, April 16, 2021 /PRNewswire/
Shenzhen Chipscreen Biosciences, a China headquartered biopharmaceutical company developing and marketing novel drugs based on its unique technology of Chemical Genomics Drug discovery platform, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1b/2 clinical trial of Chiauranib/CS2164, a potential treatment for multiple oncological indications including Small Cell Lung Cancer (SCLC), Ovarian Cancer, Liver Cancer, and Breast Cancer, etc. Chiauranib is the third novel drug candidate discovered and developed by Chipscreen to be marketed, submitted NDA or in the late-stage phases of clinical studies.
Date Time
UPMC Hillman Names New Hematology Oncology Chief
PITTSBURGH – Taofeek K. Owonikoko, M.D., Ph.D., will join the UPMC Hillman Cancer Center and Department of Medicine at the University of Pittsburgh as chief of the Division of Hematology/Oncology. Owonikoko, a physician-scientist board-certified in medical oncology, hematology and internal medicine, also will serve as associate director for translational research and co-leader of the Cancer Therapeutics Program at Hillman. He will hold the Stanley M. Marks – OHA Endowed Chair in Hematology/Oncology Leadership and will begin his appointment on July 1, 2021.
“Taofeek has an extraordinary track record of clinical and academic success and a deep commitment to helping early career researchers and clinicians achieve their fullest potential,” said Robert Ferris, M.D., Ph.D., director of UPMC Hillman Cancer Center. “We are thrilled he is joining the senior leadership team at Hillman.”
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA) biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.